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The Fc Region of an Antibody Impacts the Neutralization of West
Nile Viruses in Different Maturation States
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Michael S. Diamond,c,d,e Daved H. Fremont,b,c Theodore C. Piersona
Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USAa; Department of Biochemistry
and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, USAb; Department of Pathology and Immunology, Washington University School
of Medicine, St. Louis, Missouri, USAc; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USAd; Department of Molecular
Microbiology, Washington University School of Medicine, St. Louis, Missouri, USAe
Flavivirus-infected cells secrete a structurally heterogeneous population of viruses because of an inefficient virionmaturation
process. Flaviviruses assemble as noninfectious, immature virions composed of trimers of envelope (E) and precursor mem-
brane (prM) protein heterodimers. Cleavage of prM is a required process during virionmaturation, although this often remains
incomplete for infectious virus particles. Previous work demonstrated that the efficiency of virionmaturation could impact anti-
body neutralization through changes in the accessibility of otherwise cryptic epitopes on the virion. In this study, we show that
the neutralization potency of monoclonal antibody (MAb) E33 is sensitive to the maturation state ofWest Nile virus (WNV),
despite its recognition of an accessible epitope, the domain III lateral ridge (DIII-LR). Comprehensive epitope mapping studies
with 166 E protein DIII-LR variants revealed that the functional footprint of MAb E33 on the E protein differs subtly from that
of the well-characterized DIII-LRMAb E16. Remarkably, aromatic substitutions at E protein residue 306 ablated the maturation
state sensitivity of E33 IgG, and the neutralization efficacy of E33 Fab fragments was not affected by changes in the virionmatu-
ration state. We propose that E33 IgG binding onmature virions orients the Fc region in a manner that impacts subsequent anti-
body binding to nearby sites. This Fc-mediated steric constraint is a novel mechanism by which the maturation state of a virion
modulates the efficacy of the humoral immune response to flavivirus infection.
Flaviviruses are a group of single-stranded, positive-sense, en-veloped RNA viruses that annually infect over 390 million in-
dividuals worldwide (1). West Nile virus (WNV), a mosquito-
transmitted virus that is amember of this genus, causes a spectrum
of diseases in humans and other vertebrate animals that ranges
from a self-limiting febrile illness to severe meningitis or enceph-
alitis (2, 3). Roughly 25% of infected humans become symptom-
atic, and the elderly and immunocompromised are at greatest risk
for severe, potentially fatal outcomes (2, 4, 5). Although WNV is
typically associated with a modest number of human cases each
year, intense local outbreaks with significant morbidity and mor-
tality have occurred (6). Despite WNV’s global distribution and
potential to cause significant disease, there are no vaccines or ther-
apeutics available for use in humans.
The11-kb flavivirus RNAgenome is containedwithin spher-
ical enveloped virions that are covered by a dense arrangement of
180 envelope (E) proteins (Fig. 1A) (7, 8). The viral genomic RNA
is translated as a single polyprotein and is cleaved by cellular and
viral proteases into three structural proteins (E, precursor mem-
brane [prM], and capsid [C]) and seven nonstructural proteins
(9). Flaviviruses assemble at the rough endoplasmic reticulum
(ER) and bud into the lumen as immature virus particles. The
surfaces of the virions include 60 trimeric spikes formed from
heterodimers of the prM and E structural proteins (Fig. 1A, left)
(9–11). To become infectious, flaviviruses undergo a maturation
process prior to egress (12, 13). When immature virus particles
traffic from the ER to the low-pH environment of the trans-Golgi
network, the E proteins collapse to form 90 homodimers orien-
tated roughly parallel to the virion surface (Fig. 1A, center) (14,
15). This rearrangement exposes a site on prM that allows for
cleavage by a cellular furin-like protease into pr and M (13). The
cleaved pr peptide dissociates from the virion when it is released
into the neutral extracellular space, resulting in the formation of a
relatively smooth, infectious, mature virus particle that retains
only the M peptide (14) (Fig. 1A, right). Although the cleavage of
prM during maturation is necessary for acquisition of infectivity,
depending on the cell type this process may be inefficient (16–21).
Indeed, flavivirus-infected cells secrete a structurally heteroge-
neous population of infectious virions with varied degrees of prM
cleavage (22–24).
Crystal structures of several flavivirus E proteins have been
solved, all of which revealed a common molecular architecture
consisting of three domains (25–30) (Fig. 1B). Domain I (DI)
organizes the elongated E protein structure by linking domains II
and III (DII andDIII) via a-barrel. On the distal end ofDII is the
hydrophobic fusion loop that facilitates the merging of viral and
host lipid bilayers during viral membrane fusion (31). Finally,
DIII has an immunoglobulin-like fold and contains a lateral ridge
(DIII-LR), composed of four loops (DE, BC,N-terminal loop, and
FG) (Fig. 1B and C), that protrudes from the surface on mature
virions (32). The solvent accessibility of this region suggests a role
for the DIII-LR in interacting with host attachment and/or entry
receptors. Indeed,mutationswithin this region alter virulence and
cellular tropism (33–35).
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Studies from many laboratories have established that the hu-
moral immune response is critical for the prevention and control
of flavivirus infections (36–44). The majority of neutralizing an-
tibodies are directed against the E protein; neutralizing monoclo-
nal antibodies (MAbs) that target each of the three domains
within the E protein have been characterized (reviewed in refer-
ence 45). To neutralize infection, antibodies must simultaneously
engage an individual virion with a stoichiometry that exceeds a
critical threshold (46). Studies with WNV E DIII-LR MAbs have
suggested that approximately 30 antibodies are required for neu-
tralization (47). Within this framework, two parameters act in
concert to define conditions under which neutralization is possi-
ble. First, antibody affinity determines the fraction of accessible
epitopes occupied at a given antibody concentration (48, 49). The
second factor is the accessibility of the epitope on the virus particle
for antibody engagement.
Differences in the arrangement of E proteins on mature, par-
tially mature, and immature virions introduce a level of complex-
ity with regard to the accessibility of epitopes on the virion. The
prM content of infectious virions alters sensitivity to neutraliza-
tion by many classes of antibodies (50). For example, the DII-FL
MAbE53 only efficiently neutralizesWNVparticles retaining high
levels of uncleaved prM (50, 51). In contrast, the neutralization
potencies of DIII-LR MAbs E16 and E24 are insensitive to the
maturation state of the virus particle (50). These data are in agree-
ment with structural models of flavivirus virions that suggest the
DIII-LR epitope remains accessible to solvent irrespective of the
maturation state. Unexpectedly, we recently discovered a DIII-LR
MAb whose neutralization activity was modulated by the level of
uncleaved prM on the surface of the virion. We investigated the
functional mechanism by which the maturation state of WNV
modulates the efficacy of an antibody that recognizes the accessi-
ble DIII-LR epitope of the E protein. Our study shows that the Fc
region of aDIII-LR antibody can affect binding and neutralization
ofmatureWNVvirions. This provides a newmechanismbywhich
the maturation state of a virion can impact the efficacy of the
humoral immune response to flavivirus infection.
MATERIALS AND METHODS
Cell culture.HEK-293T cells were cultured in a low-D-glucose (1 g/liter)
formulation of Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing HEPES (Invitrogen) that was supplemented with 7% fetal bovine se-
rum (FBS; HyClone) and 100U/ml penicillin-streptomycin (P/S; Invitro-
gen). Raji-DCSIGNR cells were cultured in RPMI 1640 medium
containing Glutamax (Invitrogen) that was supplemented with 7% FBS
and 100 U/ml P/S. Cell lines were maintained in the presence of 7% CO2
at 37°C.
Measurement of antibody functional affinities.Antibody functional
affinities to WNV reporter virus particles (RVPs) was measured using an
indirect enzyme-linked immunosorbent assay (ELISA). High-protein
binding ELISA plates (Reacti-Bind; Thermo Scientific) were coatedwith 1
g/ml of humanized E16 (hE16) MAb under alkaline conditions (0.2 M
CO3
2/HCO3
, pH 9.4) for 16 h at 4°C. ELISA plates containing immo-
bilized hE16 were blocked with bovine serum albumin (BSA; in 1 phos-
phate-buffered saline [PBS], 0.05%Tween 20, 1%BSA) for at least 2 h and
then washed (1 PBS, 0.05% Tween 20). Supernatants containing WNV
RVPs were diluted in RPMI 1640, added to hE16-coated wells, and incu-
bated at 25°C for 2 h. All wells were then washed (1 PBS, 0.05% Tween
20). Ten serial 2-fold dilutions of primary MAbs (MAb E16, E33, or E60)
were then added and incubated at 25°C for 1 h. Following incubation, all
wells were washed (1 PBS, 0.05% Tween 20) and, for secondary detec-
tion, horseradish peroxidase (HRP)-antibody conjugate (0.2 g/ml; goat
FIG 1 The WNV E protein undergoes conformational rearrangements during maturation. (A) Model of the cryo-electron single-particle reconstructions of
immature flavivirus virion at near-neutral pH (left), immature flavivirus virion at acidic pH (center), andmature flavivirus virion at near-neutral pH. TheWNV
E protein domain I is shown in red, domain II is in yellow, and domain III is in blue. The fusion loop (FL) located within domain II is shown in green. The prM
protein is shown in purple. (B) The crystal structure of the WNV E protein, with domains colored as above. In addition, the four loops comprising DIII-LR are
labeled. (C) The WNV E protein domain III, displaying the 14 amino acids selected for our saturation-mutagenesis studies.
Lee et al.
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anti-mouse HRP; Thermo Scientific) was added and the mixture was in-
cubated for 1 h. All wells were then washed (1 PBS, 0.05% Tween 20).
Ultra TMB-ELISA peroxidase substrate (Thermo Scientific) was added
and themixture was incubated for approximately 10 to 15min. Reactions
were quenchedwith 2MH2SO4, and absorbance at 450 nmwasmeasured
by using a SpectraMax M5 plate reader (Molecular Devices). Apparent
antibody affinity was estimated using a rectangular hyperbola curve that
described the equilibrium binding between WNV RVPs and an antibody
as a functon of increasing antibody concentration (Prism;GraphPad Soft-
ware).
Generation of WNV DIII-LR saturation mutagenesis plasmid li-
brary. A previously described plasmid (pCBWN) carrying the New York
1999 WNV prM-E structural genes was used as a mutagenesis template
(52). Primers designed to introduce a degenerate codon (NNN) at nucle-
otide positions corresponding to selected amino acids were synthesized
(Invitrogen) and employed in site-directed mutagenesis reactions with
the PfuUltra DNA polymerase system (Agilent Technologies). PCR mix-
tures were treated with DpnI (New England BioLabs) for 1 h at 37°C,
transformed into Stbl2 Escherichia coli cells (Invitrogen), and spread on
LB plates containing 100g/ml of carbenicillin. All bacterial propagation
was performed at 30°C. A total of 48 colonies were selected from each
reaction mixture, and their plasmids were isolated by using a Spin mini-
prep kit (Qiagen). Colonies were screened by sequencing the specific gene
regions of interest (Macrogen Corporation, Rockville, MD). Typically,
this approach yielded from 13 to 16 unique mutants for each codon,
although this efficiency varied significantly as a function of the number of
possible codons for each amino acid mutation. To complete the satura-
tion mutagenesis library, a second round of PCR amplification experi-
ments was performed with primers designed to introduce the specified
mutations not isolated in the first screen. Ultimately, the full sequence of
the prM-E genes from all plasmids within the library were confirmed by
DNA sequencing. Furthermore, once the library was completed, 20% of
plasmids within the library were selected at random and subjected to
confirmatory sequencing over the region of interest.
Production of WNV RVPs. WNV RVPs were produced as described
previously (50). Furin RVPs were produced by transfection of HEK-293T
cells withDNAplasmids carrying theWNVcapsid pCBWN,human furin,
and aWNV lineage II (strain 956) replicon expressing GFP (53) in a ratio
of 30:1:10:10 bymass. NH4Cl RVPs were produced in a similar manner as
described here, except the plasmid carrying human furinwas replaced (on
a weight-by-weight basis) with pcDNA3.1. All transfections were per-
formed using Lipofectamine LTX and Plus reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. For both furin and NH4Cl RVP
preparations, the media were exchanged 4 h following transfection with
low-glucose DMEM containing HEPES that was supplemented with 7%
FBS and 100 U/ml P/S. For NH4Cl RVP preparations, culture medium
was supplemented to a final concentration of 20 mMNH4Cl dissolved in
1 PBS. Furin RVPs were produced at 30°C, while NH4Cl RVPs were
produced at 37°C. Culture supernatant containing WNV RVPs was har-
vested serially every 24 h between 24 and 96 h posttransfection, filtered
through a 0.22-m filter, and stored at 80°C. Following each serial
harvest, low-glucose DMEM containing HEPES supplemented with 7%
FBS and 100 U/ml P/S was added.
Measuring the titer of WNV RVPs. Ten serial 2-fold dilutions of
WNVRVPs were used to infect Raji-DCSIGNR cells at a concentration of
1 105 cells/well in a total volumeof 200l. InfectedRaji-DCSIGNRcells
were incubated at 37°C for 36 to 48 h, after which infectivity was assessed
by determining the percentage of cells expressing GFP via flow cytometry.
Estimates of titers weremade using only linear portions of the curve of the
RVP concentration versus the percentage of infected cells.Maximal infec-
tivity was defined as the infectivity on Raji-DCSIGNR of neat RVP-con-
taining supernatant.
Neutralization assays. Stocks of RVPs of a determined titer were di-
luted in a manner sufficient to infect between 1% and 3% of Raji-
DCSIGNR cells. This condition ensured antibody excess at informative
portions of the dose-response curve. Diluted RVPs weremixed with serial
4-fold dilutions of the MAb in duplicate. Antibody-RVP mixtures were
incubated at 37°C for 1 h to achieve binding equilibrium, added to 1 105
Raji-DCSIGNR cells, and incubated at 37°C for 36 to 48 h in a total vol-
ume of 300 l. Infectivity was assessed by determining the percentage of
cells expressing GFP based on flow cytometry. The concentration of anti-
body required to inhibit 50% of infection (EC50) was estimated by regres-
sion analysis. Data were fit with a sigmoidal dose-response curve (variable
slope), where the top of the curve was constrained to 100 and the bottom
to 0 (Prism; GraphPad Software).
Production of Fab fragments. Fab fragments were generated from
purified MAbs by using a Fab fragment preparation kit (Thermo Scien-
tific) as specified by the manufacturer. Purified MAbs were incubated for
5 to 6 h at 37°C with papain at pH 6.6 to generate Fab fragments. Fab
fragments were purified by negative selection using a protein A column
and concentrated by using a 30-kDa molecular mass cutoff centrifugal
device (Amicon). The purities of the products were assessed via nonre-
ducing SDS-PAGE. Fab fragments were stored at 4°C. Concentrations
were measured based on the absorbance at 280 nm, with an estimated
extinction coefficient (1-mg/ml solution) of 1.4.
RESULTS
Maturation state-dependent neutralization by a WNV DIII-LR
antibody.WNVRVPs are pseudo-infectious virions produced by
genetic complementation of a subgenomic replicon encoding
GFP with viral structural genes (C, prM, and E) expressed in trans
(53). This technology has been utilized extensively to study anti-
body-mediated neutralization of flaviviruses (47, 50, 54–57).
RVPs produced under standard conditions are inherently hetero-
geneous with respect to the efficiency of virion maturation, and
thus they are composed of unknown ratios of mature, immature,
and partially mature virus particles. To study the impact of virion
maturation on antibody-mediated neutralization with more ho-
mogenous populations of virions representative of each end of the
maturation spectrum, we produced RVPs under conditions that
either enhanced or impaired the efficiency of prM cleavage (50,
58). To create particles that approximated mature virions, exoge-
nous human furin protease was overexpressed in RVP-producing
cells (furin RVPs). In contrast, the synthesis of RVPs approximat-
ing immature virions required the addition of NH4Cl to a final
concentration of 20 mM (NH4Cl RVPs). NH4Cl raises the pH
within the trans-Golgi network, which prevents the structural re-
arrangements of the E protein necessary for prM cleavage (59).
To investigate the impact of the maturation state of WNV on
antibody-mediated neutralization, 20 serial 2-fold dilutions of
DIII-LR-specific MAbs E16 and E33 or the DII-FL-specific MAb
E60 were incubated in parallel with either furin or NH4Cl RVPs
for 1 h at 37°C. The resulting immune complexes were then added
to Raji-DCSIGNR cells, and the infectivities of the two popula-
tions of RVPs in the presence of each of the three MAbs were
determined by flow cytometry analysis. As anticipated from prior
studies (50), E16 neutralized furin andNH4Cl RVPswith a similar
potency (Fig. 2A andD). In contrast, neutralization of furin RVPs
required 6.2-fold more E33 (n  36; P  0.0001) than did prM-
containing NH4Cl RVPs (Fig. 2B and E). Both E16 and E33 neu-
tralized NH4Cl RVPs with similar efficacies. In agreement with
previous findings, E60, which recognizes an epitope that is cryptic
onmature virions, displayed a reduced capacity to neutralize furin
RVPs compared to NH4Cl RVPs that retained significant quanti-
ties of uncleaved prM (Fig. 2C and F) (50). Analysis of the differ-
ences between the log10 EC50 values of furin and NH4Cl RVPs
neutralized by E16, E33, and E60 revealed that E33 defines a novel
Neutralization of West Nile Virus
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class of maturation state-sensitive antibodies that binds a solvent-
accessible epitope on the surface of the mature virion (Fig. 2G).
MAbE33bindsmature andNH4ClRVPswith a similar func-
tional affinity. The neutralization potency of an antibody is gov-
erned in part by the affinity of epitope recognition. The affinity of
a MAb to any E protein epitope is complicated by the quaternary
structure of the virus particle, whichmay in turn bemodulated by
the extent of virion maturation. To determine if differences in
functional affinity were responsible for maturation state-sensitive
properties of E33, indirect ELISAs using furin and NH4Cl RVPs
were performed. If the maturation state-sensitive property of
MAb E33 were driven by differences in functional affinity for its
epitope on furin and NH4Cl RVPs, we would anticipate a 6.2-fold
difference in Kd values derived from our indirect ELISAs. How-
ever, E16, E33, and E60 had comparable functional affinities to
both populations of RVPs (n  5) (Table 1). These data suggest
the the apparent affinity of antibody recognition alone does not
govern the differential neutralization sensitivity seen with MAb
E33 against furin and NH4Cl RVPs.
Variants revealDIII-LR tolerates extensivemutagenesis.The
details of the interaction between E16 and WNV DIII have been
defined using biochemical, functional, and structural methodol-
ogies (40, 60). In contrast, residues on theDIII-LR that contribute
FIG 2 TheWNV E protein DIII-LRMAb E33 is maturation state sensitive. (A to C) Twenty 2-fold serial dilutions of MAbs E16 (A), E33 (B), and E60 (C) were
incubated with either furin RVPs (blue) or NH4Cl RVPs (red) for 1 h at 37°C to achieve binding equilibrium. Immune complexes were then added to
Raji-DCSIGNR cells, and infectivity was assessed 36 to 48 h postinfection by flow cytometry. Results shown were normalized to infectivity in the absence of
antibody. Error bars display the standard errors of duplicate infections. Data are representative of 36 independent experiments. (D to F) The arithmetic mean
log10(EC50) values for MAbs E16 (D), E33 (E), and E60 (F) for furin or NH4Cl RVPs from all 36 independent, parallel experiments are displayed. Errors bars
display the standard errors. (G)Differences in log10(EC50) values between furin andNH4Cl RVPs neutralized by E16, E33, or E60. The differences were calculated
from the arithmetic means of 36 independent experiments. Statistical analysis was performed using Prism software (GraphPad). The differences in log10(EC50)
values between furin and NH4Cl RVPs neutralized by E16, E33, or E60 were compared by using a one-way analysis of variance followed by Tukey’s multiple
comparison test. The dashed line indicates the lower limit of detection. ****, P 0.0001.
TABLE 1 Functional affinities of MAbs E16, E33, and E60 for furin and
NH4Cl RVPs
MAb
Affinity (Kd [nM]) for RVPs of
a:
Furin NH4Cl
E16 0.15	 0.04 0.20	 0.06
E33 0.09	 0.06 0.08	 0.03
E60 0.14	 0.08 0.61	 0.60
a Values are means	 standard errors.
Lee et al.
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to neutralization by E33 have not been extensively studied. A com-
parison of the E16 and E33 functional footprints, defined as those
residues that when mutated impact the neutralization of virions
by antibodies, might provide insight into the mechanism(s) that
contributes to the maturation state sensitivity of antibodies that
bind surface-accessible epitopes, such as the DIII-LR. To this end,
we sought to identify residues that comprise the E33 functional
footprint by using a saturation-mutagenesis approach. A total of
14 residues that are within and adjacent to the DIII-LR were se-
lected for study and mutated to each of the remaining 19 amino
acids (Fig. 1C). The selection of these residues was guided by res-
idues previously implicated in DIII-LR recognition by antibodies
(61–68), the structure of the DIII-LR antibody E16 bound to
WNV DIII (40, 60, 69), and residues involved in forming the sol-
vent-accessible loops of the DIII-LR itself (25, 29). Furthermore,
because weak noncovalent interactions between the antibody and
the polypeptide main chain could contribute functionally to the
epitope, both surface-accessible and buried residues that aid in the
formation of the overall architecture of the region were selected.
Mutations were introduced into a WNV prM-E expression plas-
mid by site-directed mutagenesis using degenerate primers (see
Materials and Methods). We created a library where all 20 amino
acids for each of the 14 target residues were expressed, resulting in
a collection of 266 WNV DIII-LR mutants.
Each mutant plasmid was used to create furin RVPs by com-
plementation with plasmids expressing capsid and a subgenomic
replicon encoding a GFP reporter gene (53). The infectivity of
each variant was determined by titration on Raji-DCSIGNR cells
and compared to the WT RVPs that were produced in parallel. In
order to examine broad trends in the data, each variant was placed
into one of seven categories based on the chemical identity of its
mutant residue. This organization scheme revealed that the target
residues of interest could be partitioned into one of three catego-
ries based on their ability to tolerate mutations. A limited number
of residues (C305 and Y329) did not tolerate any mutations, as
none of the mutants were infectious (Fig. 3A and D). Several res-
idues (Y302, F309, andD333)withstoodmutations to amino acids
only within the same chemical group (Fig. 3B and D). However, a
majority of residues (n  9) tolerated mutation to almost any
other amino acid without marked adverse effects (Fig. 3C and D).
Maturation-sensitive MAb E33 recognizes a distinct func-
tional epitope on the DIII-LR. We utilized this panel of WNV
mutants to determine the functional epitope of MAb E33. To do
so, we generated furin RVPs of panels of viable mutants at posi-
FIG 3 The infectivities of DIII-LR mutants partition into three patterns and reveal functional plasticity. (A to C) Ten 2-fold serial dilutions of a panel of
saturationmutants at E protein residuesC305 (A), Y302 (B), andQ391 (C)were added toRaji-DCSIGNRcells. The variantswere divided into seven groups based
on the chemical identity of the mutant side chain. The residues G and A were classified as small amino acids (red); S, T, and C are nucleophilic (light blue); V, L,
I, M, and P are hydrophobic (purple); F, Y, and W are aromatic (orange); D and E are acidic (dark blue); Q and E are amides (green); H, K, and R are basic
(brown). Infectivity of the mutants was assessed 36 to 48 h postinfection by flow cytometry and normalized to the maximal infectivity of the wild-type control.
Results are representative of at least two independent experiments. (D) Relative infectivities of mutants, compared to the wild type. Green, yellow, and red tiles
indicate a2-fold,10-fold, or100-fold difference inmaximal infectivity compared to the wild type, respectively. Blue tiles represent the wild-type infectivity
data. Results were compiled from at least two independent experiments with independent RVP preparations.
Neutralization of West Nile Virus
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tions 306, 307, 310, 311, 330, 332, 366, 390, and 391. These posi-
tions were selected from the original 14 residues of interest since
amino acids from all seven different chemical groups could be
expressed without markedly altering infectivity compared toWT.
Parallel neutralization studies with E16, E33, and E60 were per-
formed on each mutant. To ensure that our saturation-mutagen-
esis approach could unambiguously determine a functional foot-
print, E16 was included in each experiment as a positive control.
Furthermore, the maturation state-sensitive MAb E60 also was
included as a control to ensure that mutations introduced within
or adjacent to the DIII-LR did not perturb either the quaternary
structure of the virion or the efficiency of prM cleavage. Since E60
recognizes an epitope that includes theDII-FL,we anticipated that
the EC50 for this antibody toward any of the DIII-LR variants
would be comparable to that for theWT.All neutralization studies
were performed in parallel, at least two times, using independently
produced furin RVPs. A representative neutralization study using
the library of S306 variants is shown in Fig. 4. Mutations at this
position increased, decreased, or had no effect on neutralization
potencies of E16 or E33. Analysis of the E60 data revealed that
none of the mutations markedly altered the EC50 of this MAb,
suggesting that the quaternary structure of the E proteins in the
presence of these mutations was not altered compared to theWT.
Furthermore, ourMAbE60 control ensured that all of the variants
tested possessed comparable maturation states.
In order to utilize data collected from neutralization studies to
map the functional footprint of DIII-LR antibodies, we developed
an analysis metric to assign residues as major, minor, or noncon-
tributors based on the magnitude of changes in EC50 values
among variants of the different chemical groups described above.
Residues were identified as “major contributors” if at least one
mutant from five or more chemical groups reduced the neutral-
ization potency of E16 or E33 by at least 10-fold. “Minor contrib-
utors” were residues where at least one mutant from five or more
chemical groups impaired the neutralization sensitivity of MAb
E16 or E33 by at least 2-fold. Residues that did not meet the afore-
mentioned criteria were classified as noncontributors to the
epitope. By utilizing the benchmark of five chemical groups, we
aimed to ensure a rigorous analysis metric. We reasoned that if a
residue contributed to the footprint of an antibody, alterations to
several different side chain chemistries should perturb the neu-
tralization sensitivity.We excluded from these analysis criteria the
entire chemical group to which theWT residue belonged, because
those amino acid substitutions do not significantly alter the chem-
istry of the side chain. Suchmutants should not affect the neutral-
ization potency of either E16 or E33.
Based on these analysis criteria, the residues S306, K307, and
T332 were implicated in the functional footprints of both E16 and
E33 (Fig. 5A to C). While structural studies suggested that E16
engages residues within all four loops of the DIII-LR, our results
highlight that only a subset of these crystallographically defined
contacts are functionally important for antibody-mediated neu-
tralization. Additionally, our functional data closely corroborated
epitope mapping data for E16 derived from yeast surface display
studies (40, 60). Although S306, K307, and T332 comprised the
functional epitopes of E16 and E33, these two antibodies did not
recognize all three residues in a comparablemanner. For instance,
aromatic (F, Y, and W) and basic (H, K, and R) mutations at
residue S306 increased the neutralization potency ofMAbE33 but
decreased neutralization byMAb E16 (Fig. 5A). Furthermore, any
FIG 4 Parallel neutralization studies of MAbs E16, E33, and E60 against a panel of 19 S306 mutants. Ten 4-fold serial dilutions of MAbs E16, E33, and E60 were
incubated with the S306 panel of mutant WNV RVPs that were produced under conditions of furin overexpression (i.e., furin RVPs) for 1 h at 37°C to achieve
binding equilibrium. Immune complexeswere added toRaji-DCSIGNRcells, and infectivitywas assessed 36 to 48 hpostinfection by flow cytometry. Results were
normalized to infectivity in the absence of antibody. Results are representative of at least three independent experiments performed in parallel. Shown
are neutralization curves for each of the 19 mutants at S306 and MAb E16 (top row), E33 (middle row), and E60 (bottom row). Curves for wild-type data are
shown in black, and mutant curves are colored according to the scheme described in the Fig. 3 legend.
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mutation at residue K307 abrogated the neutralization potency of
MAb E33 by at least 1,000-fold. In contrast, E16 had only dimin-
ished neutralization efficacy when assayed using the panel of K307
variants; most impaired neutralization by approximately 10-fold
or less (Fig. 5B). On the contrary, both E16 and E33 were compa-
rably sensitive to mutations at position T332, as evidenced by
similar EC50 changes for the mutants studied (Fig. 5C).
Whereas only three residues within the DIII-LR were impli-
cated as important to virion neutralization by MAb E16, four ad-
ditional residues were found to contribute to the MAb E33 func-
tional footprint: K310, T330, T366, and Q391 (Fig. 5D to G).
Residues T330 and T366weremajor contributors to the E33 func-
tional footprint, as several mutations reduced the neutralization
sensitivity by greater than 10-fold. Not all DIII-LR target residues
FIG 5 Mapping reveals that MAbs E16 and E33 recognize distinct functional epitopes on the surface of DIII-LR. Ten 4-fold serial dilutions of MAbs E16, E33,
and E60 were incubated with the indicated panel of mutantWNV RVPs that were produced under conditions of furin overexpression. RVPs and antibody were
incubated for 1 h at 37°C to achieve binding equilibrium. Immune complexes were added to Raji-DCSIGNR cells, and infectivity was assessed 36 to 48 h
postinfection by flow cytometry. Shown are mean fold differences in the EC50 compared to that for the wild type, using E16 (top row) and E33 (bottom row) to
neutralizemutants at positions 306 (A), 307 (B), 332 (C), 310 (D), 330 (E), 366 (F), 391 (G), 311 (H), and 390 (I). Error bars display the standard errors of at least
two parallel, independent experiments. Bold dashed lines indicate a 2-fold difference, which was the limit of detection. Fine dashed lines indicate a 10-fold
difference.Mutants that were noninfectious or had low levels of infectivity (i.e.,
100-fold difference inmaximal infectivity compared towild type) were omitted
from the functional mapping studies.
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tested impacted E16 andE33 neutralization;mutation of F311 and
E390 had no functional consequences on E16 and E33 potencies
(Fig. 5H and I). From this analysis, E33 possesses a functional
footprint that includes residues from all four loops of theDIII-LR.
This functional footprint is subtly different from that ofMAbE16.
Mutations at position 306 reverse the maturation state-sen-
sitive properties ofMAbE33.Our neutralization studies revealed
that aromatic substitutions at residue S306 increased the neutral-
ization efficacy of MAb E33 (Fig. 5A). These effects were compa-
rable in magnitude to the difference in the EC50 of MAb E33 for
furin versus NH4Cl RVPs. To investigate whether changes in res-
idue S306might affect thematuration state-sensitive properties of
E33, neutralization studies were performed usingMAbs E16, E33,
and E60 and both furin and NH4Cl RVPs with S306F, S306Y, or
S306WEprotein variants incorporated. Aromatic substitutions at
position S306 unexpectedly conferredmaturation state sensitivity
toMAbE16 (1.7- to 3.2-fold difference; n 6;P 0.05) (Fig. 6A).
In contrast, all three aromatic mutations at S306 abrogated the
maturation state-sensitive properties ofMAb E33 (6.2- to 1.8-fold
difference; n  6; P  0.0001) (Fig. 6B). Although MAb E60 is
sensitive to the maturation state of the virion, the aromatic muta-
tions at residue S306 did not affect the neutralization efficacy of
E60 (Fig. 6C). This MAb was able to neutralize S306F, S306Y, and
S306W NH4Cl RVPs approximately 200-fold more effectively
than furin RVPs, and these results were comparable to those ob-
tained with WT furin and NH4Cl RVPs.
To our surprise, these data demonstrated that the maturation
state-sensitive property of MAb E33 is not fixed and can be mod-
ulated independently of the quantity of uncleaved prM on the
virus particle. It is possible to increase the neutralization potency
of MAb E33 against furin RVPs by expressing any one of three
aromatic residues at S306, so that it is comparable to the efficacy
observed with NH4Cl RVPs. In contrast, these mutations did not
have an effect on MAb E60, whose maturation state-sensitive
properties remained static. Although S306 was not classified as a
major contributor to the E16 or E33 footprint, this residue can
significantly abrogate the maturation state-sensitive properties of
MAb E33.
Fc-mediated steric occlusion modulates maturation sensi-
tivity of DIII-LR MAb E33. While our mutagenesis studies re-
vealed differences in how E16 and E33 engage the “same” DIII-LR
epitope, these details do not in themselves explain differences in
thematuration state dependence of these two antibodies.We next
considered whether aspects beyond the epitope-paratope inter-
face affect antibody occupancy. To investigate the role of the re-
mainder of the antibodymolecule inmodulatingmaturation state
sensitivity, we examined the extent to which furin or NH4Cl RVPs
were neutralized by Fab fragments derived from E16, E33, and
E60. Fab fragments generated from E16 neutralized furin and
NH4Cl RVPs with comparable potencies (Fig. 7A and B). How-
ever, this was also true for fragments generated from MAb E33.
The difference in neutralization potency by E33 Fab between furin
and NH4Cl RVPs was 1.1-fold (n  6). These data contrast with
those for the intact E33 IgG, which had a maturation state-sensi-
tive pattern of neutralization. Although the MAb E60 is also a
maturation state-sensitive antibody, the Fab fragments did not
affect this property (Fig. 7A). Similar to experiments using aro-
matic mutants at E protein residue 306, the maturation state-
sensitive properties of E33 could bemodulatedwithout changes to
the prM content of the particles; E60 IgG remained maturation
state sensitive.Our data suggest that the presence of the Fc domain
on MAb E33 confers the property of differential neutralization
between furin and NH4Cl RVPs.
DISCUSSION
Flaviviruses are structurally heterogeneous targets for antibody
recognition (54, 70). While antibody affinity for viral antigens is
an important parameter that helps define the neutralization po-
tency of an antibody, the accessibility of epitopes for antibody
binding is also a critical and variable factor. In particular, many
epitopes recognized by neutralizing antibodies are not predicted
to be accessible using existing models of the mature virus particle.
This limits the neutralizing potential of many classes of antibod-
ies, even at saturating concentrations (47, 50, 71).
We have shown previously that the inefficiency of virion mat-
uration alters the landscape for antibody recognition by increas-
ing the accessibility of otherwise cryptic determinants (50). In-
creasing the efficiency of the maturation process decreases the
potency of neutralization of several classes of antibodies, includ-
ing those binding the DII fusion loop. We proposed that the pro-
FIG 6 Aromatic mutations at residue 306 abrogate the maturation-sensitive properties of MAb E33. Ten 4-fold serial dilutions of MAbs E16, E33, and E60 were
incubated with either furin RVPs or NH4Cl RVPs for 1 h at 37°C to achieve binding equilibrium. Immune complexes were then added to Raji-DCSIGNR cells,
and infectivity was assessed 36 to 48 h postinfection by flow cytometry. Results were normalized to infectivity in the absence of antibody. The differences in
log10(EC50) values between furin and NH4Cl RVPs for wild type, S306F, S306Y, and S306W neutralized by MAbs E16 (A), E33 (B), or E60 (C) are shown. Error
bars display the standard errors of six independent experiments performed in parallel using at least three independent RVP preparations. Statistical analysis was
performed using Prism software (GraphPad). The differences in log10(EC50) values between furin and NH4Cl RVPs neutralized by E16, E33, or E60 were
compared using one-way analysis of variance followed by Tukey’s multiple comparison test. The dashed line indicates the lower limit of detection. ns, P
 0.05;
*, P 0.05; ****, P 0.0001.
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cess of maturation reduces the number of accessible epitopes on
the average virion, often below theminimum required to exceed a
stoichiometric threshold. This would result in a large fraction of
viruses that are no longer sensitive to neutralization, even with
saturating concentrations of antibody (47, 50). However, in this
study, we identify a MAb (E33) that was sensitive to the extent of
virionmaturation yet bound an epitope predicted to be accessible
on E proteins of both mature and immature virus particles. The
functional affinities of MAb E33 toward its epitope on furin and
NH4Cl RVPs were comparable; therefore, the maturation state
sensitivity cannot be explained by affinity alone.
To investigate the underlying mechanism for the maturation
state-sensitive pattern of E33, we created a functional map of its
epitope. This was accomplished by first generating a large library
of virions with mutations incorporated at 14 residues of the DIII-
LR. Analysis of the infectivity of these mutants revealed that the
DIII-LR could tolerate extensive variation. At nine of the positions
selected for study, it was possible to produce infectious virus par-
ticles that had incorporated almost any amino acid substitution
without deleterious effects on infectivity. It is important to note
that the functional studies described within were performed using
a cell line for which virus attachment is mediated by interactions
with the c-type lectin DC-SIGNR. As DIII has been directly impli-
cated in interactions of flaviviruses with cellular factors during
binding and entry (72, 73), it will be of interest to repeat the anal-
ysis of the infectivity of this panel of viruses on other cellular
substrates for which the mode of attachment may differ. Further-
more, our recent studies suggest that not all cell types are equally
sensitive substrates for detection of maturation state-dependent
patterns of neutralization, due to the impact of uncleaved prM on
the efficiency of virus-cell interactions (S. Mukherjee and T. Pier-
son, unpublished data).
The interaction of E16with theWNVDIII-LRhas been studied
extensively. Crystallographic studies have demonstrated that rec-
ognition is dominated by side chain and water-mediated hydro-
gen bonds between E16 complementarity-determining region
(CDR) loops and 18 residues within DIII (40). Remarkably, our
mapping studies and analysis metrics only implicated the residues
S306, K307, and T332, which are localized on the BC and N-ter-
minal loops, as functionally important to E16 neutralization of
virions. Strikingly, these data highlight that not all contacts re-
vealed by structural studies have functional consequences and un-
derscore the importance of cautious interpretation of such data.
Our studies with E33 suggest the functional epitope of this
MAb overlaps with E16 but also extends to include amino acids in
the DE and FG loops. In addition to S306, K307, and T332, our
studies suggest that residues K310, T330, T366, and Q391 also
contribute to the E33 functional footprint (Fig. 8). Although our
mapping studies are extensive, we anticipate that further satura-
tion-mutagenesis and parallel neutralization studies will elucidate
the functional footprints with higher resolution. However, in ju-
diciously selecting residues of interest, we covered a significant
portion of the total surface area that exists within and adjacent to
the DIII-LR. These studies also illustrated the complexity by
FIG 7 Fab fragments generated from MAb E33 do not show maturation-sensitive neutralization. Ten 4-fold serial dilutions of MAb or Fab fragments were
incubated with either furin (blue) or NH4Cl RVPs (red) for 1 h at 37°C to achieve binding equilibrium. Immune complexes were then added to Raji-DCSIGNR
cells, and infectivity was assessed 36 to 48 h postinfection by flow cytometry. Shown are the mean log10(EC50) values for MAbs E16 (left graphs), E33 (middle
graphs), and E60 (right graphs) neutralization of furin and NH4Cl RVPs using MAb (A) or Fab (B) fragments.
FIG 8 Functional footprints of MAbs E16 and E33. The WNV E protein
domain III with the amino acids within MAb E16 (left) and MAb E33 (right)
functional footprints displayed are shown. Residues implicated by our map-
ping data and analysis metrics to be part of only the MAb E33 functional
footprint are highlighted in red.
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which two MAbs bind to what appears at first sight to be similar
epitopes on the virion.While both E16 and E33 recognized a com-
mon set of amino acids on the DIII-LR, they appeared to do so
differently. Aromatic and basic mutations at S306 increased MAb
E33 neutralization efficacy while having the opposite effect on
MAb E16. Furthermore, anymutation at K307 impaired E33 neu-
tralization sensitivity by at least 1,000-fold, whereas the effects of
these same mutants on E16 were modest.
Ourmodel to explain thematuration state-dependent neutral-
ization of E33 arose in part from differences in how E16 and E33
recognize the DIII-LR. Onmature virions, the angle at which E33
IgG engages with the virion may position the antibody molecule
such that it introduces steric obstacles to antibody occupancy not
experienced during binding of E16 IgG on the virus particle. Ar-
omatic substitutions at residue S306 increased the sensitivity of
mature WNV RVPs to neutralization by E33 and, surprisingly,
rendered the antibody insensitive to the maturation state of the
virion. Since aromatic side chains are among the most bulky
amino acids, it is possible that the S306F, S306Y, and S306Wmu-
tations altered the angle of engagement of E33 with the DIII-LR.
Indeed, we also found that comparably bulky mutations (S306H,
S306K, and S306R) rendered MAb E33 maturation state insensi-
tive (data not shown). Furthermore, our hypothesis is supported
by the observation that aromatic mutations conferred a slight
maturation state sensitivity to the MAb E16. Examination of the
crystal structure of theDIII-LR and E16 revealed steric constraints
when aromatic side chains weremodeled at position 306 (data not
shown). Finally, reducing the size of the antibody molecule
through removal of the Fc domain eliminated the impact of virion
maturation on E33 neutralization.
Structural studies of HIV and influenza virus antibodies have
demonstrated that it is possible to engage similar epitopes with
markedly different modes of recognition. For example, the potent
and broadly neutralizing HIV-1 antibodies 4E10 and 10E8 recog-
nize a conserved helix at the C terminus of HIV-1 fusion protein
gp41 (74, 75). While both MAbs engage a common set of six res-
idues, 4E10 also interacts with an additional set of four residues
that nest around the common core. High-resolution structural
studies have revealed marked differences in the mechanism of
MAb binding, including pronounced alterations in the angle of
approach. We predict that a similar phenomenon occurs with the
DIII-LR MAbs E16 and E33.
In summary, we have identified a MAb that recognizes the
DIII-LR epitope in a maturation state-dependent manner. As this
epitope is fully accessible on the virion and is the target of anti-
bodies shown to be functionally insensitive to the prM content of
the virion, this result was unexpected. Our comparison of the data
between the two maturation state-sensitive antibodies, E33 and
E60, underscores the incompleteness of an accessibility paradigm
to describe the impact of uncleaved prM on the sensitivity of viri-
ons to neutralization. Unlike MAb E60, it is not a decrease in the
quantity of solvent-accessible epitopes, per se, that governs the
MAb E33 maturation state sensitivity. Our data support a model
by which this sensitivity to the prM content of the virus particle is
explained by steric constraints imposed by the Fc domain upon
MAb binding to the DIII-LR. We propose that the E33 Fc region
impairs the ability of MAbs to engage nearby epitopes that are
otherwise surface accessible and thereby impacts how antibodies
dock on the virion and in what numbers. This is a novel mecha-
nism by which the maturation state of a flavivirus virion impacts
the neutralization potency of an antibody that binds a solvent-
exposed epitope.
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